Lv4
760 积分 2025-02-10 加入
The Klotho proteins in health and disease
15小时前
待确认
The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic
15小时前
待确认
FGF-based drug discovery: advances and challenges
15小时前
待确认
Therapy for Fibrotic Diseases: Nearing the Starting Line
20天前
已完结
Epidemiology of metabolic dysfunction-associated steatotic liver disease
20天前
已完结
Efruxifermin in Compensated Liver Cirrhosis Caused by MASH
1个月前
已完结
Impact of Supervised and Structured Diet and Exercise in Management of Patients with Metabolic Dysfunction Associated Steatohepatitis– A Randomized Controlled Trial
1个月前
已关闭
Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial
1个月前
已完结
Interaction of inflammation and portal hypertension in cirrhosis progression
1个月前
已完结
Placebo Rates in Metabolic Dysfunction–Associated Steatohepatitis Clinical Trials: A Systematic Review and Meta-Analysis
1个月前
已完结
皖公网安备34019202002308
